NLRP3 inflammasome

The NLRP3 inflammasome is a multiprotein cytosolic complex of the innate immune system that senses diverse danger signals — metabolic crystals, pathogen products, and mitochondrial damage — and responds by activating caspase-1, which cleaves pro-IL-1β and pro-IL-18 into their mature secreted forms, and cleaves gasdermin-D (GSDMD) to form plasma-membrane pores driving pyroptotic cell death. It is one of the most studied molecular drivers of inflammaging — the chronic, low-grade, sterile inflammation that accumulates with age and fuels cardiovascular, metabolic, and neurodegenerative disease.

The inflammasome concept was first articulated by Tschopp and colleagues in 2002 ¹, and NLRP3 was identified as a key inflammasome-forming sensor in 2004 ².

Complex structure and assembly

The NLRP3 inflammasome consists of three core components:

Component	Gene	Role
NLRP3 sensor	NLRP3 (CIAS1)	Pattern recognition; PYD + NACHT + LRR domains; senses activation signals
ASC adaptor	PYCARD	PYD–PYD bridge (NLRP3 → ASC) + CARD–CARD bridge (ASC → pro-caspase-1); forms the ASC speck
Pro-caspase-1	CASP1	Effector; oligomerizes via CARD–CARD interaction; auto-activates upon oligomerization

Upon activation, NLRP3 oligomerizes, recruits ASC through PYD–PYD interactions, and ASC in turn nucleates pro-caspase-1 recruitment via CARD–CARD contacts. The resulting ASC speck is a large (~1 µm) perinuclear structure visible by immunofluorescence and serves as the catalytic platform for caspase-1 autoactivation. One speck forms per cell upon activation. Atomic protein pages: asc (R24d), caspase-1 (R24d), gsdmd (R24d), il-1b (verified), il-18 (R25). nlrp3-protein remains an implicit stub. Family-completion siblings now seeded: il-1a (R25; SASP-apex cytokine, NLRP3-independent), il-1ra (R25; endogenous IL-1 receptor antagonist), il-1r1 (R25; receptor for IL-1α/β + IL-1Ra).

Two-signal model of activation

NLRP3 activation requires two temporally distinct signals:

Signal 1: Priming (transcriptional)

The first signal is provided by pattern recognition receptors — typically Toll-like receptors (TLRs) detecting PAMPs (microbial products) or cytokine receptors detecting TNF-α, IL-1β, or IL-18. This signal activates NF-κB, which drives transcriptional upregulation of both NLRP3 and pro-IL-1β (both are NF-κB target genes). Without priming, resting NLRP3 levels are insufficient for inflammasome assembly.

Signal 2: Assembly (post-translational)

The second signal triggers conformational change in NLRP3 and ASC speck nucleation. Multiple stimuli converge on a small number of proximal mechanisms:

Potassium efflux — the most conserved proximal trigger; diverse NLRP3 activators share K⁺ efflux as a required step
Lysosomal destabilization / cathepsin B release — activated by crystalline particles (see DAMPs below)
Mitochondrial dysfunction — mitochondrial ROS, released mitochondrial DNA (mtDNA), and cardiolipin on the outer mitochondrial membrane all activate NLRP3
GSDMD-dependent secondary pores — once activated, GSDMD pores amplify K⁺ efflux, creating a feed-forward loop

DAMPs and PAMPs activating NLRP3

Activator class	Examples	Disease relevance
Cholesterol crystals	Oxidized LDL-derived crystals	atherosclerosis — macrophage foam-cell NLRP3 ³
Monosodium urate (MSU)	MSU crystals in gout	Acute gout flares
β-amyloid fibrils / oligomers	Aβ1-42	alzheimers-disease — microglial NLRP3 ⁴
Islet amyloid polypeptide (IAPP)	Pancreatic amyloid	type-2-diabetes — beta-cell IL-1β
Silica / asbestos fibers	Environmental crystalline particles	Silicosis, mesothelioma
Bacterial pore-forming toxins	Nigericin, aerolysin	Infectious inflammation
ATP (extracellular)	Released from damaged cells	Purinergic danger signal via P2X7R → K⁺ efflux
Mitochondrial DAMPs	mtDNA, cardiolipin, ROS	NLRP3 in sterile inflammation and aging

Effector outputs

Activated caspase-1 cleaves three classes of substrates:

Pro-IL-1β → mature IL-1β — potent pro-inflammatory cytokine; acts via IL-1R1 on multiple cell types to amplify NF-κB signaling, recruit neutrophils, and drive systemic acute-phase response
Pro-IL-18 → mature IL-18 — promotes IFN-γ production by NK and T cells; elevated in cardiovascular and metabolic disease
Gasdermin-D (GSDMD) N-terminal fragment — inserts into the plasma membrane as a ~16 nm pore; allows unconventional secretion of mature IL-1β/IL-18; at high activation levels drives pyroptotic cell death (cell lysis, DAMPamplification)

Aging relevance

Inflammaging

NLRP3 is a central effector node of inflammaging. With aging, multiple NLRP3-activating signals accumulate simultaneously: mitochondrial dysfunction increases mtDNA leakage and ROS; cellular senescence generates DAMPs as part of the SASP (senescent cells release IL-1α, which can prime NLRP3 in neighboring cells); cholesterol crystals accumulate in vessel walls; and gut microbiome dysbiosis increases circulating LPS (TLR4 priming). The net result is chronically primed and sporadically activated NLRP3 driving the chronic IL-1β/IL-18 milieu characteristic of aged tissue.

Dimension	Status
Pathway conserved in humans?	yes
NLRP3 gain-of-function → age-like inflammation in humans?	yes (CAPS genetics)
Replicated in humans (CANTOS)?	yes — IL-1β inhibition reduces MI (Ridker 2017)

Atherosclerosis

Foam-cell macrophages in atherosclerotic plaques ingest cholesterol crystals and other lipid aggregates, activating NLRP3. Duewell et al. (2010) showed using bone-marrow transplant experiments in Ldlr⁻/⁻ mice that NLRP3 and ASC in bone-marrow-derived cells are required for early atherosclerotic lesion formation: NLRP3-KO and ASC-KO bone marrow recipients had ~69% lower aortic sinus lesion area than wild-type bone marrow controls (P<0.0001). The mechanism involves phagolysosomal rupture by cholesterol crystals releasing cathepsin B/L, which activates NLRP3 ³. Note: cholesterol crystals activate NLRP3 in LPS-primed macrophages; priming (Signal 1) is still required in vitro. Human proof-of-concept came from the CANTOS trial (Ridker 2017): canakinumab (anti-IL-1β monoclonal antibody) administered to patients with prior myocardial infarction and elevated hsCRP reduced recurrent MI at the 150 mg dose (HR 0.85, 95% CI 0.74–0.98, p=0.021) without lowering LDL cholesterol — establishing that the IL-1β/NLRP3 arm of inflammation causally contributes to atherosclerotic cardiovascular events in humans ⁵. (CANTOS HR and CI values are reported on nf-kb as verified; verify against the PDF at local path before relying on these exact figures.)

Type 2 diabetes

Pancreatic islet amyloid (IAPP deposits) and high-fat diet-driven adipose tissue inflammation both activate NLRP3 in macrophages and, to some degree, in beta cells themselves, generating local IL-1β. IL-1β impairs insulin secretion and promotes beta-cell apoptosis, contributing to the progressive beta-cell failure that characterizes type-2-diabetes. This observation underpins trials of anakinra and canakinumab in T2D. needs-human-replication — mouse data strong; human IL-1 blockade trials in T2D have shown modest glycemic effects, not yet replicated at scale.

Alzheimer’s disease

In the Alzheimer’s brain, β-amyloid (Aβ) fibrils and oligomers activate NLRP3 in microglia. Heneka et al. showed in APP/PS1 mice that NLRP3 deficiency reduces amyloid plaque burden (~70% reduction in FA-extractable Aβ at 16 months), skews microglia toward an M2 phagocytic phenotype, and preserves spatial memory (Morris Water Maze) and LTP ⁴. The paper also showed strongly elevated cleaved caspase-1 in human MCI and AD brain tissue compared to controls. Tau phosphorylation reduction was not reported in Heneka 2013 and should not be attributed to this study. unsourced — tau phosphorylation link needs separate citation. ASC specks released extracellularly seeding Aβ aggregation is a later finding (Venegas et al. 2017, Nat Med) not established by Heneka 2013. needs-human-replication — mouse models robust; human genetic data limited (no common NLRP3 variants with established AD risk).

Dimension	Status
Pathway conserved in humans?	yes
NLRP3 → neuroinflammation/AD phenotype?	yes (mouse models)
Replicated in humans?	in-progress (NLRP3-inhibitor CNS trials planned; no Phase 2/3 data yet)

Cardiac aging and heart failure

NLRP3 activation is elevated in failing human and mouse hearts. Senescent cardiomyocytes (CM senescence, see cardiomyocytes) activate NLRP3 in recruited macrophages via SASP components, and CM pyroptosis contributes to myocardial remodeling under pressure overload and ischemic injury. The non-canonical, Tgfb2/Gdf15/Edn3-only SASP of CMs (Anderson 2019) does not include IL-1β directly, but NLRP3 in neighboring immune cells can be activated by CM-derived DAMPs (mtDNA, ATP). no-mechanism — the specific DAMPs linking aged CMs to myocardial NLRP3 activation have not been directly demonstrated.

Genetic disorders: CAPS

Gain-of-function mutations in CIAS1 (the gene encoding NLRP3) cause Cryopyrin-Associated Periodic Syndromes (CAPS), a spectrum of Mendelian autoinflammatory disorders ⁶:

Syndrome	Severity	Features
FCAS (Familial Cold Autoinflammatory Syndrome)	Mild	Cold-triggered urticaria, fever, arthralgia
MWS (Muckle-Wells Syndrome)	Intermediate	Periodic fever, urticaria, sensorineural deafness, amyloidosis
CINCA/NOMID	Severe	Chronic neonatal-onset multisystem inflammatory disease

All three syndromes respond dramatically to IL-1 blockade (anakinra, canakinumab, rilonacept), providing unambiguous human genetic proof that constitutive NLRP3 activation drives pathology — and validating IL-1β as the key effector downstream of NLRP3.

Therapeutic angles

Agent	Target	Mechanism	Approval / Stage	Evidence level
Anakinra	IL-1R1 (blocks IL-1α + IL-1β)	Competitive receptor antagonist (recombinant IL-1Ra)	FDA-approved (CAPS, RA, NOMID)	Strong (CAPS); limited (aging applications)
Canakinumab	IL-1β (monoclonal)	Neutralizes secreted IL-1β	FDA-approved (CAPS, gout, SJIA); CANTOS Phase 3 ⁵	Strong (CAPS, CV); limited (T2D, AD)
Rilonacept	IL-1α + IL-1β (soluble receptor trap)	Decoy receptor fusion protein	FDA-approved (CAPS)	Strong (CAPS); no aging trial data
MCC950	NLRP3 directly	Inhibits NLRP3 ATPase / conformational change; blocks ASC speck formation	Preclinical (no human trials) ⁷	Preclinical only; needs-human-replication
Colchicine	Microtubules (pleiotropic)	Inhibits NLRP3 assembly (indirect); anti-neutrophil; anti-crystal phagocytosis	FDA-approved (gout); LoDoCo2 trial CV outcomes positive	Limited (gout-NLRP3 link established; CV mechanism multi-mechanism)
Senolytics	Senescent cells (upstream)	Eliminate SASP source that primes/amplifies NLRP3 activation	Preclinical-to-Phase-2 (senolytics)	Preclinical; human trials limited

MCC950 / CMPD-4

MCC950 (also called CMPD-4) is the most widely used selective NLRP3 inhibitor in preclinical research. Coll et al. showed it blocks NLRP3 ASC speck formation and IL-1β release in macrophages and in multiple mouse models of NLRP3-driven disease without affecting NLRC4, AIM2, or NLRP1 inflammasomes ⁷. No human clinical trials have been reported as of 2026. needs-human-replication dose-response-unclear

Canakinumab / CANTOS

The CANTOS trial (Ridker 2017) enrolled 10,061 patients with prior MI and hsCRP ≥2 mg/L and randomly assigned them to canakinumab 50/150/300 mg subcutaneous every 3 months vs placebo. The 150 mg dose met the primary MACE endpoint (HR 0.85, 95% CI 0.74–0.98, p=0.021). The 300 mg dose also reduced cancer incidence and mortality (Lancet companion paper — separate endpoint, separate statistical analysis). Increased fatal infection risk was observed (incidence rates ~0.31 vs 0.18 per 100 person-years; HR ~1.31). The trial established human causal proof for IL-1β in atherosclerotic events, independent of LDL lowering ⁵.

Limitations and open questions

NLRP3 and aging in humans: while strong mechanistic evidence links NLRP3 to inflammaging in rodents, direct human intervention data beyond CAPS and atherosclerosis (CANTOS) is sparse. needs-human-replication
Tissue-specific NLRP3 biology: macrophage/microglia-centric studies may underrepresent NLRP3 roles in non-immune cells (cardiomyocytes, neurons, adipocytes). no-mechanism in several tissue contexts
MCC950 translation: no human-grade NLRP3 inhibitor has completed Phase 2 trials as of 2026. Infectivity risk (paralleling canakinumab’s fatal infection signal) is a concern for chronic use in aging populations. long-term-unknown
NLRP3 vs other inflammasomes: aged tissue may also involve NLRC4, AIM2, NLRP1, and non-canonical caspase-4/5 pathways; NLRP3-centric therapeutic targeting may be incomplete. needs-replication

Cross-references

This pathway intersects with:

chronic-inflammation — NLRP3 as the molecular effector of inflammaging
nf-kb — Signal 1 priming; downstream of IL-1β secretion (paracrine feed-forward)
sasp — Senescent-cell SASP provides both priming signals (IL-1α) and DAMPs
atherosclerosis — cholesterol crystal NLRP3 activation in foam-cell macrophages
type-2-diabetes — islet/adipose NLRP3 in beta-cell loss and insulin resistance
alzheimers-disease — Aβ-driven microglial NLRP3 and ASC speck seeding
microglia — primary NLRP3-expressing cell type in the CNS
cardiomyocytes — non-canonical SASP and cardiac NLRP3 context
senomorphics — IL-1β inhibition as senomorphic strategy
pyroptosis — effector cell death mode downstream of GSDMD cleavage (stub)
caspase-1 — effector caspase; protein page planned (stub)
il-1b — primary cytokine output; protein page planned (stub)
gsdmd — pore-forming executioner; protein page planned (stub)
asc — adaptor bridging NLRP3 and pro-caspase-1; protein page planned (stub)

Footnotes

doi:10.1016/s1097-2765(02)00599-3 · Martinon F, Burns K, Tschopp J · Mol Cell 2002 · in-vitro · model: THP-1 cell-free system + 293T reconstitution + dominant-negative in differentiated THP-1 cells · coined the term “inflammasome”; demonstrated NALP1/Pycard/caspase-1/caspase-5 complex by gel filtration (~700 kDa); showed Pycard (ASC) is essential for caspase-1 and caspase-5 activation; DN-Pycard blocked LPS-induced IL-1β maturation in vivo; NALP1 is the founding member — NLRP3 (NALP3) is mentioned as related but is not studied as an inflammasome component in this paper · 5,880 citations · archive: local PDF available at (local PDF))00599-3.pdf ↩
doi:10.1016/s1074-7613(04)00046-9 · Agostini L et al. (Tschopp lab) · Immunity 2004 · in-vitro · model: 293T reconstitution + THP-1 endogenous inflammasome + monocytes from a single MWS patient (R260W mutation) · demonstrated NALP3 (NLRP3) forms an inflammasome with ASC, Cardinal (CARD8), and caspase-1, but NOT caspase-5 (key distinction from the NALP1 inflammasome); NALP3-induced caspase-1 activation is strictly dependent on ASC; macrophages from the MWS R260W patient spontaneously secreted active IL-1β even without LPS stimulation, supporting constitutive inflammasome activation as the pathogenic mechanism; anakinra treatment of these patients abolished symptoms within hours · 1,726 citations · archive: local PDF available at (local PDF))00046-9.pdf ↩
doi:10.1038/nature08938 · Duewell P et al. · Nature 2010 · in-vivo + in-vitro · model: ApoE⁻/⁻ mice (confocal early-lesion study) + lethally irradiated Ldlr⁻/⁻ mice reconstituted with NLRP3-KO, ASC-KO, or IL-1α/β-dKO bone marrow (n=7–9/group), fed high-fat diet 8 weeks · cholesterol crystals appear as early as 2 weeks after atherogenic diet in ApoE⁻/⁻ mice, correlated with macrophage accumulation (r²=0.99, P<0.001); cholesterol crystals activate NLRP3 via phagolysosomal membrane rupture + cathepsin B/L release; NLRP3-KO and ASC-KO bone marrow recipients showed ~69% reduction in average aortic sinus lesion area vs WT bone marrow controls (P<0.0001); cholesterol crystals without LPS priming did not release IL-1β (priming required for in-vitro activation); IL-18 plasma levels also reduced in KO reconstituted mice · 3,809 citations · archive: local PDF available at (local PDF) ↩ ↩²
doi:10.1038/nature11729 · Heneka MT et al. · Nature 2013 (published Jan 2013; PMC manuscript) · in-vivo · model: APP/PS1 transgenic mice crossed with Nlrp3⁻/⁻ (n=15) or Casp1⁻/⁻ (n=14) vs APP/PS1 WT (n=14) and WT controls (n=16); all on C57Bl/6 background; 16-month-old animals · NLRP3 or caspase-1 deficiency: (1) reduced Aβ plaque burden and FA-extractable Aβ (~70% reduction in formic-acid-soluble Aβ); (2) improved spatial memory (Morris Water Maze, probe trial day 9, p<0.05); (3) prevented LTP suppression (p<0.001); (4) skewed microglia to M2 phenotype with enhanced Aβ phagocytosis; (5) increased IDE expression. Also showed elevated cleaved caspase-1 in human MCI (n=8) and AD (n=12) brain vs controls (n=8). Tau phosphorylation was NOT reported as an outcome in this paper — do not attribute that claim here. · 2,736 citations · archive: local PDF available at (local PDF) ↩ ↩²
doi:10.1056/NEJMoa1707914 · Ridker PM et al. (CANTOS Trial) · NEJM 2017 · rct · n=10,061 · model: humans with prior MI and hsCRP ≥2 mg/L · canakinumab 150 mg q3mo: HR 0.85 (95% CI 0.74–0.98, p=0.021) for MACE vs placebo; no LDL change; fatal infection rate increased (~0.31 vs 0.18/100 person-yr) · established human causal proof for IL-1β in atherosclerotic events · 8,619 citations · archive: local PDF available at (local PDF) ↩ ↩² ↩³
doi:10.1038/ng756 · Hoffman HM et al. · Nat Genet 2001 · genetic/positional cloning · model: FCAS and MWS pedigrees (human germline), 3 FCAS families + 1 MWS family · identified CIAS1 (NLRP3) gain-of-function missense mutations in exon 3 (which encodes the NBS/NACHT domain, not the PYD-NACHT linker; mutations A439V, V198M, E627G, A352V all map to the NACHT domain per Fig. 3b); both FCAS and MWS caused by same gene; protein named cryopyrin; 920 aa, 105.7 kDa, pI 6.16; mutations absent in >100 normal controls · 1,631 citations · archive: local PDF available at (local PDF) ↩
doi:10.1038/nm.3806 · Coll RC et al. · Nat Med 2015 · in-vitro + in-vivo · model: macrophages (human + mouse) + multiple disease models (gout, T2D, peritonitis, EAE, CAPS) · MCC950 (CMPD-4) selectively inhibits NLRP3 but not NLRC4/AIM2/NLRP1; blocks ASC speck formation and IL-1β/IL-18 secretion; effective in multiple inflammatory disease models; no human trial data · 2,637 citations · archive: download pending (OA green — not yet verified against primary source; quantitative claims in MCC950 section of this page remain unverified needs-verification) ↩ ↩²

🧬 Aging Wiki

Explorer

nlrp3-inflammasome